ID   OVCAR3-533533-R5
AC   CVCL_DH39
DR   cancercelllines; CVCL_DH39
DR   GEO; GSM1186819
DR   GEO; GSM1186824
DR   GEO; GSM1186830
DR   Progenetix; CVCL_DH39
DR   Wikidata; Q54937020
RX   PubMed=24004674;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:132239; PHA-533533.
CC   Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; c.1746-2A>T; Zygosity=Heterozygous; Note=Splice acceptor mutation (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
DI   NCIt; C105555; High grade ovarian serous adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0465 ! OVCAR-3
SX   Female
AG   60Y
CA   Cancer cell line
DT   Created: 13-07-16; Last updated: 05-10-23; Version: 12
//
RX   PubMed=24004674; DOI=10.1158/1078-0432.CCR-13-1337;
RA   Etemadmoghadam D., Au-Yeung G., Wall M., Mitchell C., Kansara M.,
RA   Loehrer E., Batzios C., George J., Ftouni S., Weir B.A., Carter S.,
RA   Gresshoff I., Mileshkin L., Rischin D., Hahn W.C., Waring P.M.,
RA   Getz G., Cullinane C., Campbell L.J., Bowtell D.D.L.;
RT   "Resistance to CDK2 inhibitors is associated with selection of
RT   polyploid cells in CCNE1-amplified ovarian cancer.";
RL   Clin. Cancer Res. 19:5960-5971(2013).
//